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Autoantibodies against EPCR are found in antiphospholipid syndrome and
are a risk factor for fetal death
Vero´nica Hurtado, Ramo´n Montes, Jean-Christophe Gris, Marı´a L. Bertolaccini, A´ lvaro Alonso, Miguel A. Martı´nez-Gonza´lez,
Munther A. Khamashta, Kenji Fukudome, David A. Lane, and Jose´ Hermida
The antiphospholipid syndrome (APS) is
associated with thrombosis and fetal death
but the pathologic mechanisms are poorly
understood. Since endothelial protein C re-
ceptor (EPCR) plays a role in the anticoagu-
lant system and in placental development,
we hypothesized that anti-EPCR autoanti-
bodies may be involved in clinical manifesta-
tions of APS and in fetal loss. The levels of
immunoglobulin M (IgM) and IgG anti-EPCR
autoantibodies were analyzed by enzyme-
linked immunosorbent assay (ELISA) in 43
patients with APS and 43 controls. Anti-
EPCR levels were higher in APS patients
than in controls. Interestingly, one of the IgM
anti-EPCR autoantibodies inhibited the gen-
eration of activated protein C on endothe-
lium. Since markedly high anti-EPCR levels
were found in women with fetal death, 87
patients with a first episode of unexplained
fetal death were subsequently analyzed and
their anti-EPCR levels were compared with
87 matched controls. We found that anti-
EPCR autoantibodies constitute an indepen-
dent risk factor for a first fetal death epi-
sode: the adjusted odds ratios (ORs) for
anti-EPCR autoantibodies above the 95th
percentile were 23.0 (95% confidence inter-
val [CI], 2.0-266.3) for IgM and 6.8 (95% CI,
1.2-38.4) for IgG. Anti-EPCR autoantibodies
can be detected in APS patients and are
independent risk factors for fetal death.
(Blood. 2004;104:1369-1374)
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Introduction
Antiphospholipid syndrome (APS) is characterized by vascular
thrombosis and complications of pregnancy (fetal death, premature
birth, or multiple spontaneous abortions) associated with the
presence of antiphospholipid antibodies (APLs).1 These antibodies
are heterogeneous and recognize a variety of combinations of
phospholipids, phospholipid-binding proteins, or both.2 The most
commonly detected subgroups of antiphospholipid antibodies are
lupus anticoagulant antibodies (LACs) and anticardiolipin antibod-
ies (aCLs). Other antiphospholipid antibodies are directed against
phospholipids other than cardiolipin or against phospholipid-
binding proteins like 2-glycoprotein I or annexin V.3,4 However,
the mechanisms linking the presence of APLs with thrombosis and
pregnancy complications such as fetal death are poorly understood.
Activated protein C (APC) is a major regulatory protein of the
coagulation cascade. Protein C (PC), the zymogen of APC, is
activated by thrombin bound to thrombomodulin on cell surfaces.
APC, working in concert with its nonenzymatic cofactor protein S,
exerts its anticoagulant function by proteolyzing activated factors
V and VIII.5 Genetic and acquired defects of thrombomodulin, PC,
and protein S have been identified in patients with venous and/or
arterial thrombosis, and antibodies against these molecules have
been related with APS.6 Endothelial PC/APC receptor (EPCR) is an
endothelial cell membrane glycoprotein that is tightly bound to a
phospholipid and binds PC and APC.7,8 EPCR is mainly expressed
in large vessels, especially arteries, and in the syncytiotrophoblast
as well.9,10 PC binding to EPCR notably enhances its activation by
the thrombin-thrombomodulin complex.11 APC binding to EPCR
allows APC-dependent tethering of protease-activated receptor-1,
which blocks the apoptosis of endothelial and probably placental
cells.10,12-14 In addition, growing evidence supports a role for EPCR
in pregnancy maintenance, since EPCR knockout mice experience
placental thrombosis and early embryonic mortality.15 This fact,
together with the nature of EPCR as a phospholipid-binding
protein, its function as anticoagulant and cell protector, its involve-
ment in the development of placenta, and its localization on the
surface of vessels and placenta, makes this molecule a possible
target for APL associated with fetal death and thrombotic disease.
We investigated the presence of anti-EPCR autoantibodies in
patients with APS. The results obtained made us suspect that a
relationship between these antibodies and fetal death may exist. For
this reason, we subsequently studied the association of anti-EPCR
autoantibodies with first fetal death in a matched case-control
study. We also studied the effect of these autoantibodies on APC
generation on the endothelial surface. Our results support that
anti-EPCR autoantibodies constitute a risk factor for a first fetal
death episode. Impaired PC activation on cell surfaces could be one
of the ways by which these antibodies exert their pathologic effects.
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Patients, materials, and methods
APS patients and controls
Cases were 43 consecutive patients (ages 17-67 years; median age, 43
years; 39 women and 4 men) diagnosed with APS according to international
criteria16,17 between February 1998 and March 2002 at the St Thomas’
Hospital (London, United Kingdom). All of them were identified by having
LACs and a personal history of venous thrombosis (n  17), arterial
thrombosis (n  13), or both (n  13). Serum samples were drawn at least
3 months after the last thrombotic episode and stored at 80°C until tested
for anti-EPCR autoantibodies. The control group was composed of 43
healthy volunteers with no history of thrombosis or LACs. All patients and
controls had given their informed consent for participation in the study. The
study was approved by the Ethics Committees or Sir Thomas’ Hospital and
Clı´nica Universitaria of the University of Navarra.
Women with fetal death and controls
A matched case-control study on fetal death was carried out at the
University Hospital of Nıˆmes (France) and in clinics belonging to the same
obstetric network between September 1996 and September 2002. This
study was part of the Mediterranean Abnormal Pregnancy Study Program
that led to the previously published Nıˆmes Obstetricians and Haematologist
Study (NOHA).18
We included 87 consecutive women, 19 to 31 years old (median age, 27
years), with a first episode of fetal death from the 10th week of amenorrhea
that had occurred during their last pregnancy. Reasons for exclusion
included the following: any thrombotic antecedents, any chromosomal
abnormality in the conceptus karyotype, any morphologic malformation in
the fetus, chronic infectious disease or any known systemic disease, any
antecedents of other type of pregnancy with poor outcome (early embryo
loss before the 10th week of gestation, eclampsia, intrauterine fetal growth
restriction), diabetes mellitus, or lack of adherence to study procedures. The
fetal death had occurred during the first pregnancy in 58 women, during
the second pregnancy in 21 women, and during the third pregnancy in the
remaining 8 women; the fetal death had occurred between the 10th and
the 22nd weeks in 75 women and between the 22nd and the 36th weeks in
the remaining 12 women.
A control group of 87 healthy mothers, matched for age, number of
pregnancies, and time elapsed since the end of the last pregnancy (all
negative for thrombotic history and chronic infectious diseases), was
simultaneously recruited during the same period of time as the patients,
from consecutive women attending the outpatient Department of Gynaecol-
ogy at the same hospital for a general medical examination.
The study was approved by the Ethics Committee of the University
Hospital of Nıˆmes and the Clı´nica Universitaria of the University of
Navarra, and informed consent was obtained from all participants. Inclu-
sion of cases and controls and blood collection took place at least 6 months
after fetal death. Blood samples were collected, processed, and stored at
80°C according to standard procedures.
Expression of soluble EPCR
We amplified the soluble EPCR (sEPCR) sequence, comprising the
extracellular domain without its signal peptide and transmembrane and
intracellular domains (residues 1-193, mature protein numbering),19 by
polymerase chain reaction with primers that added ClaI and NotI restriction
sites at the 5 and 3 ends, respectively: agcttggcatatcgattagccaagacgc-
ctcagatg and tattctatgcggccgccgaagtgtaggagcggcttg. These modifications
allowed us to ligate the sEPCR sequence into the Cla and Not sites of the
plasmid pPICZC (Invitrogen, Paisley, United Kingdom) following the
Saccharomyces cerevisiae -factor secretion signal that allows for efficient
secretion of many proteins from Pichia pastoris. The insert was cloned
in-frame with a myc epitope followed by 6 histidines (His) present in the
vector in order to express the sEPCR fused with myc and 6 His at the
C-terminal end. Yeast was transformed with the linearized vector, thus
integrating the sEPCR coding sequence into the endogenous methanol-
responsive promoter by homologous recombination. As the pPICZC
vector encodes for the zeocin resistance gene, zeocin-resistant colonies of
Pichia pastoris were screened for sEPCR expression induced by 1%
methanol. The most efficient sEPCR-expressing colony was selected for
large-scale production.
Purification of recombinant sEPCR
Recombinant sEPCR was purified from culture supernatants using a 3-step
purification. The sample was loaded onto a 5-mL HiTrap chelating
high-performance (HP) column (Amersham Biosciences, Little Chalfont,
United Kingdom) loaded with copper. The bound fraction was eluted with
50 mM EDTA (ethylenediaminetetraacetic acid), dialyzed against 20 mM
Tris-HCl (pH 7.5), and then subjected to anion exchange using a Resource
Q column (Amersham Biosciences) and a salt gradient from 0 to 300 mM
NaCl over 20-column volumes. The sEPCR-containing eluted fractions
were applied to a Superdex 75-HR10/30 column (Amersham Biosciences).
The concentration of purified protein was determined using the bicincho-
ninic acid (BCA) total protein assay (Pierce, Rockford, IL).
Enzyme-linked immunosorbent assay (ELISA) for the
determination of anti-EPCR autoantibodies
Ninety-six–well microplates (Costar, Acton, MA) were coated with 0.15 g
anti-myc monoclonal antibody (MoAb; Invitrogen) to anchor sEPCR,
preserving its extracellular epitopes (direct sEPCR binding to wells
occludes several epitopes).11 After washing with Tris-buffered saline (TBS;
20 mM Tris, 150 mM NaCl, 0.05% Tween-20 [pH 7.4]), nonspecific
binding sites were blocked with 3% (wt/vol) bovine serum albumin (BSA)
in TBS. One hundred microliters per well of 1 g/mL recombinant sEPCR
in TBS supplemented with 1% BSA (TBS-BSA) were incubated at room
temperature (RT) for 4 hours. Subsequently, 100 L of a 1:100 dilution of
the sample (plasma or serum) in TBS-BSA was incubated overnight at 4°C.
Parallel blank wells were included with TBS-BSA without plasma or serum.
Bound immunoglobulin M (IgM) and IgG anti-EPCR autoantibodies were
detected with either a peroxidase-conjugated murine polyclonal antihuman
IgM (Zymed, South San Francisco, CA) or an alkaline phosphatase–
conjugated murine polyclonal antihuman IgG (Zymed). After 2 hours at
RT and extensive washing, the plates were developed with either 100 L
of 0.4 mg/mL o-phenylenediamine (IgM; Kodak, Rochester, NY) or 100
L of 1 mg/mL 4-nitrophenil phosphate (IgG; Sigma, St Louis, MO) and
read at 492 or 405 nm, respectively, in an iEMS Reader (Labsystems,
Helsinki, Finland).
To allow comparisons among plates, we chose a sample to be assayed in
every plate (standard sample), which thus allowed us to introduce a
correction factor. Arbitrary units (AUs) were defined as follows: for each
patient sample (problem sample), the specific absorbance was calculated by
subtracting the absorbance of blank wells and then multiplying by 1000 and
by a correction factor corresponding to the ratio between the absorbance of
the standard sample assayed in a given plate (reference plate) and in the
plate where the problem sample is assayed. Samples from patients were
assayed together with those from their matched controls in the same plate to
minimize differences due to the interassay variability. All samples were
assayed twice. The intra-assay and interassay coefficients of variation were
evaluated with 5 samples tested 5 and 3 times, respectively, and were
always found to be lower than 5% and 10%, respectively.
Purification of anti-EPCR autoantibodies
IgM fraction from serum or plasma samples containing high titers of IgM
anti-EPCR was isolated using a HiTrap N-hydroxy-succinimide (NHS)–
activated HP column (Amersham Biosciences) where a murine antihuman
IgM MoAb had previously been immobilized.20 IgG fraction from serum or
plasma samples containing IgG anti-EPCR was isolated using a HiTrap
protein G HP column (Amersham Biosciences) according to the manufactur-
er’s instructions.
APC generation on cultured endothelial cells
Fifty thousand EA.hy926 cells11 (endothelium-derived cell line expressing
thrombomodulin and EPCR, kindly supplied by Dr C. J. Edgell, University
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of North Carolina) were incubated with 0.02 U/mL (0.17 nM) thrombin
(ERL, Swansea, United Kingdom) and increasing concentrations of PC
(kindly supplied by Baxter, Deerfield, IL) ranging between 50 and 1000 nM
in a 20-mM Tris buffer (pH 7.4) supplemented with 150 mM NaCl, 5 mM
CaCl2, 0.6 mM MgCl2, 1% BSA, 0.01% Tween-20, and 0.02% NaN3. After
45 minutes, lepirudin (Schering AG, Berlin, Germany) was added at 0.2
M to inhibit thrombin, and 4 minutes afterward the chromogenic
substrate S-2366 (Chromogenix, Milan, Italy) was added at 0.4 mM and
its proteolysis by APC was kinetically monitored at 405 nm in the iEMS
Reader. The data curve fitting the Michaelis-Menten equation was
performed using Enzfitter software (Biosoft, Cambridge, United King-
dom), which calculated the Km and Vmax values of PC activation under
these conditions. Where required, 20 g/mL RCR-252 MoAb, which
blocks PC-EPCR binding,21 or anti-EPCR autoantibodies from patients
were added.
Preparation of a sEPCR affinity column
Two milligrams of recombinant sEPCR was coupled to a HiTrap NHS-
activated HP column (Amersham Biosciences) following the manufactur-
er’s instructions. Since the sEPCR bound to the column retained its ability
to bind PC, it probably retained the native conformation including the
epitopes recognized by the autoantibodies. Thus, this column is suitable for
anti-EPCR depleting.
Statistical methods
In the APS case-control study, the comparison between cases and controls
for frequency of high levels of IgM and IgG anti-EPCR was performed with
a chi-square test.
In the fetal death matched case-control study, comparison between
cases and controls for continuous and categoric variables was performed
with a t test for paired samples and McNemar test, respectively. Association
between levels of IgM and IgG anti-EPCR with LACs and IgM aCLs was
assessed with correlation coefficients for continuous variables and Mann-
Whitney U test for categoric variables.
In order to evaluate the risk of fetal death associated with high levels of
IgM and IgG anti-EPCR, a conditional logistic regression analysis was used
with matched pairs of cases and controls. The main independent variables
were levels of IgM and IgG anti-EPCR categorized according to the
distribution of these antibodies in controls. We used different cutoff points
to determine the levels associated with a higher risk. Univariate and
multivariate analysis were performed, adjusting for known risk factors of
fetal death. The levels of anti-EPCR autoantibodies were also divided into
quartiles to assess a relationship between this variable and risk of fetal death
(dose response). Tests for trend in fetal death across quartiles of anti-EPCR
were assessed in conditional logistic models using a continuous variable
with the median values for each quartile of the antibodies. Interaction
(effect modification) was assessed introducing product terms in the
conditional logistic models. The Mann-Whitney U test was used to compare
APC generation in the presence and absence of anti-EPCR autoantibodies.
Results
More than 5 mg of sEPCR could be purified from a Pichia culture.
By sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blot analysis, sEPCR appeared as a
single band. The PC activation by thrombin on the EA.hy926 cells
(Km  69  18 nM) was hampered in the presence of 2 M
sEPCR (apparent Ki  75  4 nM), suggesting that our recombi-
nant sEPCR binds to PC with similar efficiency to native EPCR.22,23
Furthermore, the sEPCR was able to inhibit the anticoagulant
activity of APC in a modified clotting assay, as expected22 (data not
shown). This evidence strongly suggests that our recombinant
sEPCR is folded in the correct conformation, allowing us to use it
to detect autoantibodies against EPCR.
Anti-EPCR autoantibodies in APS patients
The median values of both IgM and IgG anti-EPCR were higher among
APS cases than among controls (57 AUs vs 45 AUs and 75 AUs vs 72
AUs, respectively; Figure 1). Even if the difference between mean levels
was not statistically significant, 21% of APS patients had either IgM or
IgG anti-EPCR levels exceeding the 97th percentile compared with 5%
in control subjects (P .024). Three patients displayed very high levels
of IgM anti-EPCR (patient A 407 AUs, patient B 301 AUs, patient
C 293 AUs), and 2 patients had high IgG anti-EPCR levels (patient
D 230 AUs, patient E 220 AUs). All 5 of these patients were
women with a previous history of thrombosis. Two women carrying
IgM anti-EPCR (patients A and B) had suffered from multiple episodes
of fetal death.
Biochemical characterization of anti-EPCR autoantibodies
IgM fractions from patientsA, B, and C, and IgG fractions from patients
D and E were purified from serum. IgM fraction of patient C remarkably
inhibited the thrombin-induced APC generation by EA.hy926 cells in a
dose-dependent manner (maximum effect about 80% reduction of PC
activation; P .02), an effect comparable to that obtained with RCR-
252 (Figure 2). The decrease in the APC generation was due to an
increase in the Km rather than Vmax, compatible with ablation of the
EPCR-enhancing effect on activation (Figure 3). To demonstrate that
this effect was due to a specific IgM against EPCR, the patient C sample
was anti-EPCR autoantibody–depleted by loading it onto the sEPCR
affinity column. The sample lost the inhibitory capacity on APC
generation, indicating that a specific anti-EPCR autoantibody was
responsible for this phenomenon (Figure 2).
Anti-EPCR autoantibodies in women with fetal death
Since a relationship between anti-EPCR autoantibodies and fetal
death could be hypothesized from the results presented in the APS
study, we focused our analysis on the association between anti-
EPCR and fetal death in a group of 87 women with a first episode
of unexplained fetal death without previous history of venous
and/or arterial thrombosis and 87 healthy age-matched controls.
Table 1 shows the frequencies of risk factors classically related
with fetal death together with the frequencies of IgM and IgG
anti-EPCR found in patients and controls. The 95th percentile of
the IgM anti-EPCR in the control group was 99 AUs. Eighteen
percent of patients had values exceeding this cutoff compared with
only 3% of controls. The crude relative risk, estimated by the
matched odds ratio (OR), for fetal death in patients with IgM
anti-EPCR levels above the 95th percentile was 14.0 (95%
Figure 1. Anti-EPCR autoantibodies in APS patients and controls. Anti-EPCR
levels are shown (median, interquartile range, range, and outliers). IgM anti-EPCR:
controls, median  45 AUs; patients, median  57 AUs. IgG antibodies: controls,
median  72 AUs; patients, median  75 AUs.
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confidence interval [95% CI], 1.8-106.4) compared with those who
had a lower value. When the cutoff was set at the 90th percentile
(83 AUs), the OR was 5.2 (95% CI, 1.8-15.3).
The 95th percentile of the IgG anti-EPCR levels in the control
group was 94 AUs. Fifteen percent of patients had values exceed-
ing this cutoff compared with 5% of controls. The crude OR for
fetal death in patients with IgG anti-EPCR levels above the 95th
percentile was 4.3 (95% CI, 1.2-15.2). When the cutoff was set at
the 90th percentile (80 AUs), the OR was 2.3 (95% CI, 0.9-5.6).
In order to improve accuracy in the analysis of anti-EPCR
autoantibodies as risk factors for fetal death, we performed a
separate analysis adjusting for putative confounding variables
(Table 2). Due to the sample size, the data were sparse and we were
not able to adjust simultaneously for factor V Leiden (FVL) and
LACs in the same model. For this reason we considered 2 different
models: model 1, in which the adjustment was performed for APLs
(ie, LACs and aCLs), prothrombin G20210A, and, in the case of
IgM anti-EPCR, for IgG anti-EPCR (vice versa in case of IgG
anti-EPCR); model 2, in which FVL was included instead of LACs.
Using model 1, the OR of fetal death associated with IgM
anti-EPCR levels above the 95th and 90th percentiles were 23.0
(95% CI, 2.0-266.3) and 7.1 (95% CI, 1.9-25.6), respectively. The
ORs associated with IgG anti-EPCR levels exceeding the 95th and
90th percentiles were 6.8 (95% CI, 1.2-38.4) and 3.5 (95% CI,
1.9-11.8), respectively. In order to assess the risk associated with
anti-EPCR autoantibodies whatever the isotype was, we created a
composite variable that was either IgM or IgG level exceeding the
95th or 90th cutoff. In this way, we obtained adjusted the ORs of
10.9 (95% CI, 2.2-54.7) and 6.7 (95% CI, 2.1-21.2) with cutoffs at
95th and 90th percentiles, respectively. Using model 2 the results
were similar (Table 2).
To determine whether the relationship between anti-EPCR
autoantibody levels and the risk of fetal death was dose dependent,
we stratified the subjects into quartiles according to the anti-EPCR
levels, and OR for fetal death was calculated for each of the 3 upper
quartiles using the lowest quartile as the reference. As Table 3
shows, the adjusted OR increased monotonically with the IgM
anti-EPCR levels, suggesting a dose-response effect. However, the
adjusted OR did not increase linearly with the IgG anti-EPCR
levels, and thus a threshold response can be assumed.
Median (interquartile range) IgM and IgG anti-EPCR values
were higher in patients with LACs than in patients without LACs
(IgM, 54 [39-78] vs 82 [63-108] AUs, P  .02; IgG, 51 [37-64] vs
82 [56-117] AUs, P  .01). Likewise, levels of IgM aCLs and
anti-EPCR were positively correlated (IgM, r  0.31, P  .0001;
Figure 2. Effect of anti-EPCR antibodies on APC generation by endothelial
cells. Confluent EA.hy926 cells were incubated with buffer or the indicated Ab
(RCR-252 at 20 g/mL, the different patients’ fractions at 45 g/mL except indicated)
and the initial rate (Vo) of thrombin-dependent activation of 50 nM PC was
determined. For each condition, 2 to 4 independent experiments were performed.
The mean  standard deviation of %Vo with respect to the Vo obtained in the
absence of antibodies is represented. *P  .013, ** P  .02, with respect to the buffer
condition.
Figure 3. Effect of patient C anti-EPCR autoantibody on kinetic parameters of
APC generation by endothelial cells. Thrombin-catalyzed protein C activation on
EA.hy926 cells measured in the absence (F) or presence (E) of patient C IgM fraction
at 45 g/mL. The Km for each condition is indicated. The Lineweaver-Burk plot in the
inset shows that the Vmax in both conditions is essentially equal.
Table 2. Multivariate OR and their 95% CI for fetal death associated
with anti-EPCR levels
Anti-EPCR
antibodies and
percentile
Model 1 Model 2
Matched
OR 95% CI P
Matched
OR 95% CI P
IgM
95th 23.0 2.0-266.3 .012 31.0 2.0-384.3 .007
90th 7.1 1.9-25.6 .003 9.1 2.4-34.7 .001
IgG
95th 6.8 1.2-38.4 .029 11.0 1.6-73.5 .013
90th 3.5 1.9-11.8 .040 5.5 1.5-20.2 .010
Either IgM or IgG
95th 10.9 2.2-54.7 .004 16.9 3-96 .001
90th 6.7 2.1-21.2 .001 10.4 2.9-37.4  .001
Anti-EPCR autoantibodies were categorized using the 95th and 90th percentiles
as cutoff points for the variable in the control group. Model 1 was adjusted for
G20210A prothrombin, LACs, aCLs, and, in case of IgM anti-EPCR, for IgG
anti-EPCR (vice versa in case of IgG anti-EPCR). Model 2 is like model 1 except that
FVL is included for adjustment instead of LACs.
Table 1. Univariate OR and their 95% CI for fetal death associated
with different variables studied
Fetal death;
n 87
Controls;
n 87 Matched OR 95% CI P
IgM anti-EPCR 16 3 14.0 1.8-106.4 .01
IgG anti-EPCR 13 4 4.3 1.2-15.2 .02
FVL 6 1 6.0 0.7-49.8 .10
Prothrombin G20210A 3 1 3.0 0.3-28.8 .34
LACs 7 1 7.0 0.9-56.9 .07
IgM aCLs 9 2 5.0 1.1-22.8 .04
IgG aCLs 1 0 — — —
Anti-EPCR autoantibodies were categorized using the 95th percentile as a cutoff
point for the variable in the control group. Levels of aCLs higher than 15 G or M
phospholipid units were considered positive.
— indicates not applicable.
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IgG: r  0.24, P  .001). The crude OR of fetal death associated
with LACs (7.0) or IgM aCLs (5.0) notably decreased and lost
statistical significance when adjusting for anti-EPCR autoantibod-
ies (3.1 [95% CI, 0.3-27.9] and 2.3 [95% CI, 0.4-12.8], respec-
tively). This finding indicates that the classical APLs (LACs and
aCLs) were not independent predictors of fetal death, the apparent
increased risk associated with them being at least partly due to
anti-EPCR autoantibodies.
No interaction could be seen among the analyzed variables
(likelihood ratio test; P 	 .1). When we stratified these analyses by
the number of pregnancies or by the period in which the fetal loss
took place, the results did not substantially change.
Discussion
We developed an ELISA to detect anti-EPCR autoantibodies and
we provide evidence supporting a strong association between these
autoantibodies and the risk of fetal death. Thus for the first time the
presence of anti-EPCR autoantibodies in human pathology has
been demonstrated. First, we detected high levels of these antibod-
ies in 5 patients within a group of APS patients showing thrombosis
and LACs. Then, we provided evidence that anti-EPCR autoantibod-
ies are sometimes able to hamper the PC activation, which should
compromise anticoagulant and anti-inflammatory mechanisms.
These PC activation–blocking antibodies may probably lead to a
low level of APCs in vivo, a risk condition for thrombosis in
itself,24 which would help to explain the multiple venous thrombo-
sis episodes experienced by the patient who carried PC activation–
blocking antibodies in the APS group. Since we detected very high
levels of IgM anti-EPCR in 2 APS women with previous history of
multiple episodes of fetal death, we performed a matched case-
control study to assess the risk of having a first episode of
unexplained fetal death associated with the presence of anti-EPCR
autoantibodies. This risk was dose-dependently higher as the level
of IgM anti-EPCR increased. Very high levels of IgM anti-EPCR
constituted a strong risk factor for the first episode of fetal death,
with a 20-fold increase in relative risk. High levels of IgG
anti-EPCR were also a strong risk factor, though weaker than IgM
and without evidence for a dose-response trend. The broad
confidence intervals obtained in the estimates of the relative risks
were probably due to the reduced number of women exposed to
levels higher than the 95th percentile. Nevertheless, when a lower
cutoff (90th percentile) was set, the estimation of the risk was still
high and the confidence intervals were narrowed, the same
occurring when IgM and IgG isotypes were considered together.
This finding strongly suggests that high levels of either IgM or IgG
anti-EPCR are risk factors for fetal death. Furthermore, the
associated risk might have been underestimated, since one of the
criteria for including these patients in the study was to have neither
a previous history of venous or arterial thrombosis nor previous
obstetric complications, entities that theoretically could be associ-
ated with a higher prevalence of elevated anti-EPCR autoantibod-
ies. It is not surprising that IgM anti-EPCR was more predictive
than IgG, since this is a common feature in obstetric complica-
tions,25-27 although a likely plausible biologic explanation for this
phenomenon is not available. Known genetic risk factors, such as
FVL or the prothrombin G20210A mutation,28 did not explain the
increased risk of fetal death associated with anti-EPCR. Our
findings are also not due to the effects of LACs or aCLs. It is
noteworthy that while LACs and IgM aCLs were associated with
an increased risk of fetal death in the univariate analysis, as
previously reported,29,30 this association was markedly attenuated
and lost its statistical significance in the multivariate model, where
anti-EPCR autoantibodies were included in the analysis. Anti-
EPCR autoantibodies could thus be at least partly responsible for
the pathologic effects observed in the patients showing LACs or
aCLs. This notion is coherent with the fact that there is no plausible
explanation about how LACs or aCLs might play a pathologic role
by themselves, while anti-EPCR autoantibodies could indeed exert
a variety of pathologic effects: the binding of autoantibodies to
EPCR should be able to trigger the activation of the complement
system. This will lead to a proinflammatory state with destruction
of endothelium and trophoblast leading to a procoagulant state, and
undesirable thrombosis and fetal loss as has recently been demon-
strated in a mouse model of fetal death induced by APLs.31 On the
other hand, since the correct function of the PC system is essential
for promoting placental cell growth,10,15 it is conceivable that the
anti-EPCR autoantibodies able to block the PC activation will exert
an additional effect by reducing the APC concentration in such a
manner that the placental development will be compromised. For
these reasons, LACs and aCLs could be just innocent bystanders or
mere markers of a more complex autoimmune disorder.
In conclusion, we have demonstrated for the first time the
presence of IgM and IgG anti-EPCR in humans. High levels of
these autoantibodies are associated with a higher risk of a first
episode of fetal death. Anti-EPCR autoantibodies are often found in
patients with APS as well. It is conceivable that these antibodies
may exert a causative role in the thrombotic and the fetal death
episodes occurring in these patients.
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